NCT06980155

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

Clinical Study of XP-005 Personalized Vaccine Alone or in Combination With Toripalimab to Prevent the Relapse of Acute Myeloid Leukemia After Consolidation Therapy

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to observe and evaluate the safety and tolerability of the XP-005 personalized tumor mRNA vaccine, either alone or in combination with toripalimab, for the treatment of acute myeloid leukemia patients who are in remission with minimal residual disease (MRD) positive but cannot undergo allogeneic hematopoietic stem cell transplantation.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	Personalized neoantigen tumor vaccine	Neoantigen tumor vaccine
BIOLOGICAL	PD-1 inhibitor	Toripalimab

Timeline

• Start date: 2025-05-30
• Primary completion: 2027-01-30
• Completion: 2028-08-30
• First posted: 2025-05-20
• Last updated: 2025-05-20

Locations

1 site across 1 country: China